Key result
Gene therapy and stem cell therapies are emerging as potential treatments to halt post-infarct cardiac remodeling, though large-scale randomized trials are required to establish their clinical efficacy.
Gene and stem cell therapies offer promising new avenues for preventing post-ischemic cardiac remodeling, though robust clinical evidence of survival benefit is still pending.
No takes yet. Share an insight, caveat, or question.
Should not yet change post-MI remodeling management; leaves open gene and stem cell therapy efficacy pending large RCTs.
Sirico et al. (2015) conducted a review in Post-ischemic heart failure and cardiac remodeling. Gene therapy and stem cell therapy was evaluated. Gene therapy and stem cell therapies are emerging as potential treatments to halt post-infarct cardiac remodeling, though large-scale randomized trials are required to establish their clinical efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: